PALO ALTO, Calif., Nov. 8, 2021 /PRNewswire/ -- Kodiak Sciences
Inc. (Nasdaq: KOD), a biopharmaceutical company committed to
researching, developing and commercializing transformative
therapeutics to treat high-prevalence retinal diseases, today
announced that management will present at the following upcoming
virtual investor conferences:
- Jefferies London Healthcare Conference (pre-recorded fireside
chat available on Thursday, November
18 at 12:00 a.m. Pacific
Time)
- Evercore ISI 4th Annual HealthCONx Conference on Wednesday, December 1 at 8:45 a.m. Pacific Time
A live webcast of both presentations will be available on the
"Events and Presentations" section of Kodiak's website at
http://ir.kodiak.com/ and will remain available for replay for
a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to
researching, developing and commercializing transformative
therapeutics to treat high prevalence retinal diseases. Founded in
2009, Kodiak is focused on bringing new science to the design and
manufacture of next generation retinal medicines to prevent and
treat the leading causes of blindness globally. Kodiak's ABC
Platform™ uses molecular engineering to merge the fields of
antibody-based and chemistry-based therapies and is at the core of
Kodiak's discovery engine. Kodiak's lead product candidate,
KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being
developed for the treatment of retinal vascular diseases including
age-related macular degeneration, the leading cause of blindness in
elderly patients in the developed world, and diabetic eye diseases,
the leading cause of blindness in working-age patients in the
developed world. Kodiak has leveraged its ABC Platform to build a
pipeline of product candidates in various stages of development
including KSI-501, Kodiak's bispecific anti-IL-6/VEGF biopolymer
conjugate for the treatment of neovascular retinal diseases with an
inflammatory component, and Kodiak is expanding its early research
pipeline to include ABC Platform based triplet inhibitors for
multifactorial retinal diseases such as dry AMD and glaucoma.
Kodiak is based in Palo Alto, CA.
For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak
logo are registered trademarks or trademarks of Kodiak Sciences
Inc. in various global jurisdictions.
View original
content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-upcoming-conferences-301418960.html
SOURCE Kodiak Sciences Inc.